To take advantage of the growing knowledge of cellular signaling pathways, modern-day drug discovery faces an increasing challenge to develop assays to screen for compounds that modulate protein-protein interactions. One bottleneck in achieving this goal is a lack of suitable and robust assay technologies amenable to a high-throughput format. In this report, we describe how we utilized Alphascreen™ technology to develop a high-throughput assay to monitor ligand binding to a member of the tumor necrosis factor receptor superfamily. We expressed a fusion protein consisting of the extracellular domain of the OX40 receptor with the constant domains of human IgG. In the presence of OX40 ligand, we determined a binding affinity constant consistent with reported values and optimized the protocol to develop a simple, homogeneous, and sensitive binding assay in a 384-well format. Finally, we assessed if this system could identify small peptides capable of inhibiting the OX40 receptor and ligand interaction. The results showed that the assay was able to detect such peptides and could be used to launch a highthroughput screening campaign for small molecules able to prevent OX40 receptor activation. (Journal of Biomolecular Screening 2003:522-532) Screening NC = not calculated. The signal-to-background (S/B) ratio was calculated by dividing counts obtained in the presence of OX40L-muCD8 (100 nM) by background counts (in the absence of OX40L-muCD8). Data are expressed as the mean ± SEM (EC 50 values) and mean (S/B ratio) of 3 experiments performed in triplicate.
INTRODUCTION L IGAND BINDING INITIATES A COMPLEX CASCADE of reactions
involving protein-protein interactions, and as such, compounds that modulate these events are attractive targets for the pharmaceutical industry. 1 Indeed, there are many examples in the literature of the use of antibodies, dominant negative proteins, and peptides (10-30 amino acids) to inhibit particular protein-protein interactions. In contrast, the discovery of small "drug-like" molecules that can perform a similar function has proven difficult. 2, 3 However, despite the progress already made and the expanding potential to identify new and improved drugs, the investigation of novel and tractable protein-protein interactions is hindered by a lack of applicable assays available to screen in a high-throughput format. Ideally, suitable assays should be sensitive, robust, cost-ef-fective, and rapidly developed. Over the past few years, this bottleneck has become less problematic due, in part, to an increase in the choice and number of technologies available to allow such screening programs. Unfortunately, these are not universal solutions and are only applicable to probe some, but not all, of the desired protein-protein interactions.
Traditional biochemical techniques such as cross-linking and coimmunoprecipitation, commonly used to study membrane receptor interactions, are complex, time-consuming, and not suitable for large-scale screening studies. Classically, the most direct method to identify inhibitors of a protein-protein association is a competitive binding assay in which one of the protein partners is labeled, typically with a radioisotope. However, modern-day drug discovery is now moving away from radioactive assays to reduce cost and minimize disposal and safety issues. Consequently, biophysical in vivo approaches such as fluorescence resonance energy transfer (FRET) 4 and bioluminescent resonance energy transfer (BRET), 5 based on the nonradioactive transfer of energy between donor and acceptor molecules via the Förster mechanism, 6 have become valuable tools. These proximity-based assays have the distinct advantage of monitoring the real-time interactions of proteins synthesized in their native environment. However, both approaches require that the relevant proteins be labeled with large fluorescent or bioluminescent groups. Therefore, we chose to develop a nonradioactive, in vitro-based binding assay using pro-teins that had been only slightly modified by means of fusing to small biological linkers.
Alphascreen™ technology is a bead-based, nonradioactive amplified luminescent proximity homogenous assay that was developed initially to measure interactions between biological binding partners. 7, 8 Reagent-coated polystyrene donor and acceptor microbeads are brought into close proximity by means of a biomolecular interaction between the protein partners conjugated onto these beads. Following laser illumination, a photosensitizer in the donor bead converts ambient oxygen into a more excited singlet-state oxygen, which can diffuse a maximum distance of 200 nm before rapidly decaying. If an acceptor bead is in close proximity to the donor bead, these singlet-state oxygen molecules react with chemiluminescent groups in the acceptor bead, which immediately transfer energy to a cascade of fluorescent groups in the same bead and subsequently emit light at 520 to 620 nm.
We have used a novel approach to implement this Alphascreen technology to measure binding to a member of the tumor necrosis factor (TNF) receptor superfamily. OX40 (CD134) is a costimulatory receptor expressed selectively on activated CD 4+ T cells isolated from sites of inflammation. 9 The ligand for OX40 (OX40L) is a type II membrane protein with homology to TNF and is expressed on activated antigen-presenting cells, including B cells 10 and endothelial cells 11 but not on normal tissue. The limited cellular expression of OX40 at sites of inflammation is thought to be central to the pathogenesis of many human diseases including experimental autoimmune encephalomyelitis, 12 rheumatoid arthritis, 13 inflammatory skin diseases, 14 and graft-versus-host disease. 15 Consequently, this type I transmembrane protein has become a clinically relevant target for many pharmaceutical companies.
The therapeutic potential of modulating the interaction between OX40L and receptor was recognized by in vivo approaches, reporting that OX40-targeted immunotoxins, 16 antibodies, 17, 18 and fusion proteins [19] [20] [21] all prevented the accumulation of activated CD 4+ T cells at inflammatory sites and demonstrated beneficial anti-inflammatory effects. To identify other inhibitors of this interaction, a large screening campaign would require a biochemical approach, ideally to measure directly the association between OX40L and receptor. Documented OX40L binding assays include measurements of binding to a murine myeloma cell line using a FACScan 21 and to dextran-immobilized soluble OX40 using Biacore™ analysis. 22 Unfortunately, neither of these approaches would be well suited for a screening campaign in terms of throughput and/or cost of consumables. Consequently, we used Alphascreen technology to develop a high-throughput binding assay that was suitable to screen for selective inhibitors of OX40L binding.
We began the assay development with modified forms of OX40L and OX40 to measure binding by the use of an Alphascreen IgG (protein A) detection kit. We describe how we expressed and purified a recombinant soluble OX40-IgG fusion protein to determine the binding affinity for OX40L-CD8. Any in-teraction between these 2 proteins would bring anti-IgG-conjugated acceptor beads and streptavidin-coated donor beads into close proximity, and a signal would be detected. We developed this assay to be homogeneous, highly sensitive, robust, and suitable for automation in a 384-well format. Consequently, we were able to detect a small peptide that competitively inhibited OX40L binding. This successful approach is potentially adaptable to the development of biochemical screens for many other protein targets that interact with membrane-associated proteins, simply by expressing the extracellular portion of the relevant binding partner as an IgG fusion protein.
MATERIALS AND METHODS

Expression of recombinant human OX40-IgG 1 fusion protein
Construction of the human OX40-IgG 1 fusion protein has been described previously. 23 Briefly, the cDNA encoding the extracellular domain of OX40 from amino acid 1 to 208 was fused to the 5′ end of the cDNA encoding the constant domains of human IgG 1 (hinge region, CH2 and CH3) and subcloned into the mammalian expression vector pCEP4 (Invitrogen, Huntsville, AL). This construct was transfected into HEK-EBNA cells by the calcium phosphate method. Cells were seeded at a density of 2 × 10 5 cells/ml in growth medium (DMEM/F-12 [1:1] supplemented with 10% fetal bovine serum [FBS] and 4 mM L-glutamine). The following day, the medium was replaced by DMEM/F-12 (1:1) supplemented with 2% FBS and 4 mM L-glutamine. One hour later, cells were transfected and incubated at 37°C in a humidified atmosphere containing 5% CO 2 for 4 h, after which time the medium was changed back to the growth medium containing 10% FBS. Two days posttransfection, Hygromycin B (300 µg/ml) was added for selection. All components for the cell culture medium were purchased from Sigma Chemicals (St. Louis, MO).
Purification of recombinant human OX40-IgG 1 fusion protein
The culture supernatant was clarified by centrifugation (10 min at 500 × g) and filtered using PVDF membranes (0.45 µm and 0.22 µm pore size). In parallel, the sample was applied to a purification column containing recombinant protein-G resin (Amersham Biosciences, Buckinghamshire, UK) at a very low flow rate (typically 1 ml/min). Protein that bound nonspecifically was washed away using loading buffer (0.1 M Tris, pH 7.0). The bound fusion protein was eluted by a step gradient using 100% elution buffer (0.1 M glycine/HCl, pH 3.0), and the elution fractions were directly neutralized with 1 M Tris (pH 7.6) to prevent degradation. Finally, the pooled elution fractions containing recombinant OX40-IgG fusion protein were desalted using a Sephadex G25 column equilibrated in phosphate buffered saline (PBS). This fusion protein was stored at -80°C until required.
Assay format
The binding assay was performed using Costar ® 384-well white polystyrene plates (Corning Incorporated, Acton, MA) in a total volume of 25 µl. Unless otherwise stated, all dilutions were made in assay buffer (PBS and 0.1% bovine serum albumin) and 2% DMSO. Purified OX40L-muCD8 and anti-muCD8/Biotin were purchased from Alexis Biochemicals (Montreal, Canada). The Alphascreen IgG (protein A) kit was purchased from Biosignal Packard (Montreal, Canada).
As an initial proof of concept, we based our protocol on one previously reported to measure OX40L binding by the use of FACScan analysis. 21 Human OX40-IgG and OX40L-muCD8 were incubated together for 30 min, after which time anti-muCD8/ Biotin (10 nM) was added. Following another incubation period of 30 min, streptavidin donor beads (20 µg/ml) and protein A acceptor beads (20 µg/ml) were added to each individual well. The plate was counted 1 h later using a Packard Fusion™ reader (Biosignal Packard, Montreal, Canada) set at a read time of 1 s/well. All incubations were performed at room temperature. Owing to the light sensitivity of the donor and acceptor beads, the experiments were carried out under blue light.
For inhibition experiments, suramin (Sigma Chemicals, St. Louis, MO) and recombinant untagged OX40L (Alexis Biochemicals, Montreal, Canada) were used as positive controls. Five peptides (ranging from 24 to 31 amino acids in length) were custom synthesized (Epytop, Nîmes, France) and dissolved in water containing 0.1 mM NaOH. For these experiments, the proposed inhibitor was added at the same time as OX40L-muCD8. For the selectivity assessment of potential inhibitors, identical experiments were developed and optimized to measure binding of CD30L-muCD8 to CD30-IgG and FasL [CD95L]-muCD8 to Fas [CD95]-IgG, all purchased from Alexis Biochemicals (Montreal, Canada).
Assay performance
To monitor assay sensitivity, signal-to-noise (S/N) and signalto-background (S/B) ratios were calculated by the following equations:
To evaluate the quality of this assay for use in a high-throughput screening (HTS) campaign, performance was assessed by calculating the Z′ (and Z) value using the following equation. 
Data analyses
All K D , IC 50 , and EC 50 values were calculated using Prism ® software (Graphpad Software, Inc., San Diego, CA). The transformation of IC 50 values into K i values was performed using the Cheng-Prusoff equation. 25 
RESULTS
Principle of a biochemical assay to measure OX40L-muCD8 binding
The principle behind this assay design relies on the fact that a signal can be detected only when streptavidin donor and protein A acceptor beads are separated by a distance of less than 200 nm. As these beads are indirectly conjugated to OX40L and OX40, a binding reaction between these 2 proteins will generate a signal ( Fig. 1 ). To demonstrate appropriate binding, the IgG-tagged extracellular domain of OX40 is incubated with soluble OX40L-muCD8. Owing to the relevant tags, the receptor is able to couple to protein A acceptor beads and, in the presence of a biotinylated 
FIG. 1.
Principle of OX40 binding assay. Reagent-coated polystyrene donor and acceptor microbeads are brought into close proximity by a biomolecular interaction between proteins bioconjugated onto these beads. One complex consists of streptavidin donor beads, biotinylated anti-CD8 antibody, and CD8-tagged OX40L, and another complex is formed between protein A acceptor beads and IgG-tagged OX40. If binding occurs between OX40L and OX40, the beads are close enough to allow detection of a signal. Any inhibitors of this interaction would increase the distance between the beads, and the signal would be lost.
anti-CD8 antibody, the ligand will couple to the streptavidin donor beads. If an interaction between OX40 and OX40L occurs, an Alphascreen signal will be detected. In the presence of a compound that could compete for binding to OX40, the donor and acceptor beads will no longer be in proximity and the signal will not be detected.
OX40L binding to OX40
Initial experiments were performed to determine the feasibility of developing this assay to measure OX40L-muCD8 binding. In the first experiment, we incubated 2 different OX40-IgG concentrations with OX40L-muCD8. As shown in Figure 2A , increasing concentrations of OX40L-muCD8 dose-dependently increased the Alphascreen signal when incubated with OX40-IgG. The calculated EC 50 values (-logEC 50 ± SEM) were 7.7 × 10 -9 M (8.11 ± 0.04) and 7.9 × 10 -9 M (8.10 ± 0.01) using 5 and 10 nM of receptor, respectively. In the absence of receptor, no signal was detected.
The experiment was then repeated using a wider range of receptor concentrations (2.5-80 nM) to determine the optimal concen-tration to use for this binding assay. Seven concentrations were tested in total, and results demonstrated that each concentration generated a dose-dependent increase in the Alphascreen signal following incubation with OX40L-muCD8. In all cases, there were no significant differences between the calculated EC 50 values, but it was observed that the S/B ratio increased as the concentration of receptor increased (Table 1) , achieving a maximal level of 68 in the presence of 40 nM receptor. Higher receptor concentrations of up to 80 nM did not enhance the S/B ratio any further. The specific Alphascreen counts, calculated by subtracting background counts from total counts (obtained in the presence of 100 nM OX40L-muCD8), increased with receptor concentration and reached a maximal signal of approximately 210,000 counts with 40 nM OX40-IgG ( Fig. 2B ). No further increases in counts were obtained using higher receptor concentrations.
Taking these results into account, we decided to perform further development and optimization experiments using OX40-IgG at a concentration of 10 nM. This allowed us a good S/B window to work with and also ensured that the assay would be cost-effective by using only a minimum concentration of receptor. 
K D determination of OX40L-mu CD8 and displacement studies
We then used these conditions to calculate the K D of OX40L-muCD8 for the receptor. Nonspecific binding was determined in the presence of 1 mM suramin. This compound has been reported to promote dissociation of trimeric tumor necrosis factor (TNF) ligands into biologically inactive subunits and hence prevent an interaction with TNF receptors. 26 At this high concentration, suramin was able to completely inhibit the binding of OX40L-muCD8 to its receptor (data not shown). Thirteen different concentrations of OX40L-muCD8, ranging from 1 pM to 1 µM, were used to determine the appropriate K D value. Specific binding of OX40L-muCD8 was saturable and of high affinity, with a calculated K D value of 18.4 ± 2.8 nM (Fig. 3 ). This is in agreement with literature values in which the binding affinity of soluble CD4tagged OX40L was measured using a Biacore sensor chip method 22 and similar to K D values obtained for other members of the TNF receptor family for their respective ligands. 27, 28 We then investigated further the ability of untagged recombinant OX40L and suramin to displace bound OX40L-muCD8. As expected, neither of these compounds had any effect on the Alphascreen signal in the absence of OX40L-muCD8 (data not shown). At the approximate K D value, we performed displacement experiments with a concentration of ligand that was 4 times greater than that of the receptor. With this in mind, increasing concentrations of OX40L (0.1 pM-3 µM) or suramin (100 nM-1 mM) were added to a reaction mixture also containing OX40-IgG (10 nM) and OX40L-muCD8 (40 nM). As shown in Figure 4 , both untagged OX40L and suramin dose-dependently competed for the binding of OX40L-muCD8, with resulting IC 50 values (-logIC 50 ± SEM) of 5.9 × 10 -9 M (8.23 ± 0.35) and 7.9 × 10 -5 M (4.10 ± 0.06), respectively. These values were transformed by the Cheng-Prusoff 25 equation to K i values of 2.0 nM for untagged OX40L and 26.3 µM for suramin. This latter value for suramin is similar to reported values for inhibition of TNF-α/p55 binding to the TNF-α receptor. 26 The corresponding Hill coefficients for untagged OX40L and suramin were not significantly different from unity (-1.2 ± 0.2 and -1.0 ± 0.1, respectively).
DMSO tolerance
One important condition to define is the concentration of DMSO that the assay is able to tolerate without any loss in signal. DMSO, at final concentrations of 0.1, 0.5, 1, and 5%, dosedependently decreased the maximum number of counts when a high concentration (100 nM) of OX40L-muCD8 was incubated with OX40-IgG (2.5 ± 1.9, 6.7 ± 0.3, 14.5 ± 5.5, 60.0 ± 4.5% inhibition, respectively), indicating that 1% DMSO could be used in this assay. To evaluate any possible effect of DMSO on IC 50 values, we studied the effect of DMSO on suramin inhibition of OX40L-muCD8 (40 nM) binding to OX40-IgG (10 nM). There were no significant differences in the resulting dose-response curves, generating K i values for suramin of 21.9 ± 6.2 µM and 27.0 ± 6.9 µM in the absence and presence of 1% DMSO, respectively (data not shown). 
Further optimization of the assay
We then performed a sequence of defined experiments to optimize the assay for use in a robust, sensitive, HTS campaign. Based on the original protocol, we proceeded to investigate the possibility of reducing the number of addition steps and determined the optimal incubation time, stability of reagents, and stability of signal. Finally, we calculated Z′ and Z factor values 24 for intraplate variation and experiment-to-experiment variation, respectively.
Reduction in the number of addition steps
The present protocol required 5 addition steps to generate the Alphascreen signal. We compared the effect of combining the first 3 addition steps (OX40-IgG, OX40L-muCD8, and antibody) into 1 step and the final addition step (streptavidin donor and protein A acceptor beads) into the 2nd step by preparing both mixtures in advance to addition to the plate. We maintained a total incubation time of 60 min prior to addition of the beads and observed that the combination of 5 addition steps into 2 had no effect on the EC 50 values for OX40L-muCD8 (6.4 × 10 -9 M and 6.1 × 10 -9 M, respectively) and S/B ratio (30 and 28, respectively).
Dependence of signal on time of incubation
To determine the optimal incubation time that was required to reach equilibrium, we measured the signal generated from the incubation of OX40-IgG and OX40L-muCD8 for different time periods (30-180 min). Owing to the result of the previous experiment, we added OX40L-muCD8, OX40-IgG, and biotinylated antibody simultaneously at the beginning of the experiment. A signal could be detected after as little as 30 min incubation, with an EC 50 value in the expected range (Table 2) . Indeed, for the first 60 min, there was a linear increase in S/B ratio, with a maximal window of 32 detected after 60 min. This ratio remained constant for the following 60 min with no change in the calculated EC 50 values. During this first 120 min, we observed a linear increase in both background and total counts, such that the S/B ratio remained consistently high. However, after 180 min, only background counts in-creased with time, resulting in a slight reduction of S/B ratio to 21 but still no change in the EC 50 value. For all future experiments, we chose to use a 60-min incubation time for the binding assay.
4°C stability of stock reagent solutions
We then investigated the stability of the reagents at 4°C as they would be stored during an automated screening campaign. When assayed immediately after dilution from stock and after storage at 4°C for 4 days, OX40-IgG and OX40L-muCD8 gave similar activity in terms of EC 50 values (8.2 × 10 -9 M and 7.1 × 10 -9 M, respectively) and S/B ratios (32 and 30, respectively). Furthermore, no differences were observed between these values when using different batches of OX40-IgG and OX40L-muCD8 (data not shown).
Stability of signal
At a read time of 1 s/well, each 384-well plate takes approximately 8 min to read. We conducted an experiment to determine the maximum number of plates that could be read without any deterioration in the signal. We generated dose-response curves for OX40L-muCD8 binding by reading plates at time periods between 1 h and 12 h following addition of the donor and acceptor beads. As shown in Figure 5A , both background and maximal (in the presence of 100 nM OX40L-muCD8) counts increased over time. These sets of counts both increased at the same rate such that the S/ B ratio was still as high as 22 after 12 h (Table 3 ). When the data for each individual curve were normalized, there were no significant differences between any of the concentration-response curves generated ( Fig. 5B ) such that the calculated EC 50 values were all comparable (Table 3 ). This indicated that over a 12-h time period, at least 90 (384-well) plates could be assessed in each experiment, generating in excess of 34,000 data points.
Z-factor calculations to monitor assay performance
The Z′ factor satisfies the requirement for assessing both specific signal and precision for accurate assay performance evaluation. In general, a Z′ value >0.5 suggests that an assay is suitable for automation and a subsequent screening platform, with a Z′ value between 0.8 and 1 indicating an excellent assay. Figure 6A Effect of incubation time on EC 50 and signal-to-background (S/B) values following the simultaneous addition of OX40L-muCD8, OX40-IgG, and anti-muCD8 antibody. After the indicated incubation time, streptavidin donor and protein A acceptor beads were added, and the plates were read 1 h later. The S/B ratio was calculated by dividing counts obtained in the presence of OX40L-muCD8 (100 nM) by background counts (in the absence of OX40L-muCD8). Data are expressed as the mean ± SEM (EC 50 values) and mean (S/B ratio) of 3 experiments performed in triplicate. (Fig. 6B) , the calculated Z factor was 0.72, indicating the robustness and suitability of this assay for automation. OX40-IgG (10 nM) and OX40L-muCD8 were incubated together for 60 min before addition of streptavidin donor and protein A acceptor beads. The plates were counted 1 (¢), 3 (£), 6 (), and 12 () h following addition of the beads. A different plate was used for each time point. Data are expressed as raw counts (A) and normalized counts (B), where for each independent curve, 0% was taken as background counts (in the absence of OX40L-muCD8) and 100% was the maximal counts (in the presence of 100 nM OX40L-muCD8). Data are expressed as mean ± SEM from 3 experiments performed in triplicate. 
Peptide inhibitors of OX40L-muCD8 binding
We then performed a small screen to determine if we could identify a peptide that was able to compete for OX40L-muCD8 binding. Five peptides (PI-PV), ranging from 24 to 31 amino acids in length and spanning the extracellular fragment of OX40L, were designed in house and custom synthesized. They were tested initially at a concentration of 50 µM in a primary screen for any effect on the Alphascreen signal in the presence of OX40L-muCD8 (40 nM). Percentage inhibition of the maximal signal is tabulated in Table 4 . Peptide PV was observed to have a significant effect on OX40L-muCD8 binding, demonstrating a 73% inhibition of the maximal response, whereas PIV inhibited to a lesser extent (45%). As a result, peptides PIV and PV were investigated more thoroughly in a dose-response study (Fig. 7) . Peptide PV (31 amino acids long) competitively inhibited the Alphascreen signal generated by OX40L-muCD8 binding, with a resulting IC 50 value of 22.0 ± 12 µM, corresponding to a K i value of 7.4 µM (Hill coefficient of 1.1 ± 0.3). In contrast, the effect of PIV was far less pronounced.
To determine the selectivity of this effect, PV was tested for any inhibition of FASL binding to the FAS receptor and CD30L binding to the CD30 receptor using the same principle of the Alphascreen assay. This peptide had no effect on the binding of CD30 or FAS to their respective receptors, indicating selectivity toward OX40 (data not shown). These results suggest this peptide could specifically inhibit OX40L binding and indicate that a highthroughput screen using Alphascreen technology could be used to rapidly identify selective OX40 antagonists.
DISCUSSION
With the availability of complete genome sequences, the therapeutic potential of inhibitors of protein-protein binding has been reflected by an expanding interest from the pharmaceutical industry. Indeed, there are already examples of currently marketed drugs (tubulin inhibitors, IL-2 receptor antagonists), compounds in clinical development (LFA-1 antagonists, vitronectin receptor antagonists), and lead molecules in research programs (SH2 domain antagonists, HIV protease inhibitors) that have all been identified as inhibitors of protein-protein interactions. 3 However, a number of challenges are presented by targeting protein-protein binding in a drug discovery program. 2 From a chemical perspective, protein binding interfaces are large and relatively flat, with very few crevices into which a small molecule could fit. In terms of a biochemical screening campaign, there are many assays suitable to detect some biomolecular interactions, but very few for others. Despite this bottleneck, low-volume radioligand binding assays have been used to identify NGF antagonists 29 and CCR5 receptor antagonists. 30 Fluorescence technologies, such as fluorescence polarization and intracellular FRET studies, have also proved successful in identifying small molecules that inhibit the binding of the Bcl-2 family of proteins. 31 Furthermore, phenotypic assays have been used to identify suitable compounds that inhibit cell mitosis 32 and growth arrest. 33 However, many of these approaches require either the use of radioactivity or, if in a cellular format, that one or both proteins be labeled with large fluorescent or bioluminescent groups. We sought to develop a nonradioactive and non-cell-based assay to measure the binding of OX40L to OX40 that could be used in a fully automated high-throughput campaign to screen for inhibitors of this interaction. We achieved this goal by creating a fusion protein between the extracellular domain of OX40 and an IgG 1 tag. This short biological linker avoided the use of large labeling groups, which, in addition to being time-consuming, could have detrimental effects on the activity of the protein. In designing this fusion protein, a critical factor is the class of IgG domain used. For example, OX40IgG 4 was reported to be only half as active as OX40IgG 1 to induce antibody-dependent cell cytoxicity. This observation Data are expressed as percentage inhibition of the Alphascreen signal generated by binding of OX40L-muCD8 (40 nM) to OX40-IgG (10 nM). All peptides were added at a concentration of 50 µM and dissolved in water containing 0.1 mM NaOH. The data are expressed as mean ± SEM from 3 experiments performed in triplicate. also correlated to binding affinities, whereby OX40IgG 4 bound only half as strongly as OX40IgG 1 . 21 A binding interaction between OX40 and OX40L ensured that the Alphascreen donor and acceptor beads were brought into close proximity and a highly amplified signal was generated. Indeed, using our initial protocol, we observed dose-response curves to OX40L using as little as 2.5 nM OX40 and, at the highest concentration tested (80 nM), an S/B ratio of 68. We made a compromise between an acceptable S/B window and minimizing receptor usage and performed all further experiments using 10 nM OX40, which gave an approximate S/B of 30 to 35. The large assay window indicates the sensitivity of this Alphascreen format, deriving from the very low background fluorescence and the ability of the donor bead to generate about 60,000 singlet oxygen molecules. 7 Furthermore, the large diffusion distance of the singlet oxygen enables the detection of binding distances up to 200 nm, whereas energy transfer technologies are generally limited to detection distances of 1 to 10 nm. 34 This sensitivity was demonstrated in a recent report that directly compared Alphascreen, time-resolved FRET, and time-resolved fluorescence technologies and concluded Alphascreen to have the best sensitivity range when used to measure binding to the FXR nuclear receptor. 35 As expected, untagged OX40L and suramin were both able to competitively inhibit OX40L binding to OX40 with calculated IC 50 values similar to those reported in the literature. 26 We observed that the assay could tolerate a final DMSO concentration of 1% and optimized the conditions for automation. On the assumption that in a screening campaign, the compounds to be tested would already be present in the wells of the plate, we were able to reduce the number of addition steps from 5 to 2, the 1st step being the addition of a mixture of receptor, ligand, and antibody, followed 60 min later by a 2nd addition of a mixture of donor and acceptor beads. The signal obtained was stable for at least 12 h, allowing an excess of 90 (384well) plates, or 34,000 data points, to be read during this time period. Although we did not fully automate this assay, the Z-factor values of between 0.7 and 0.8 indicate that it would have an excellent assay performance if used for a high-throughput screen. However, we have previously validated the automation procedure for an Alphascreen cAMP assay kit. 36 As this protocol was identical to that of the present study, requiring just 2 addition steps, automation would be very rapid.
Although there are other assay formats that could be applied to measure this type of protein-protein interaction, the sensitivity and simplicity of this Alphascreen approach could be beneficial for use in a screening campaign. Both BRET and FRET technologies are emerging rapidly to be powerful tools for investigating biological interactions. In the case of FRET, both the donor and acceptor molecules are fluorescent, whereas with BRET, a bioluminescent molecule acts as the energy donor. Both applications offer the benefit of monitoring the interaction of proteins in real time in living cells, but they also have disadvantages. 37, 38 FRET can be problematic due to autofluorescence, photobleaching, and cell damage, which can result in loss of signal. BRET has great universal potential as it avoids the problems associated with excitation of a fluorophore, but as with FRET, it requires labeling of the proteins with large fluorescent and bioluminescent probes. This raises issues about the correct selection of label, the labeling process (indirect or direct), and potential effects on binding properties.
Given that our assay appeared robust and sensitive for screening, we conducted a proof-of-concept study to screen a small set of peptides spanning the OX40L sequence to identify fragments that could competitively inhibit the OX40-OX40L interaction. It has already been reported that OX40 inhibitors could have potential therapeutic relevance in several disease states. However, with the exception of immunotoxins, 12 antibodies, 17, 18 and OX40 fusion proteins, [19] [20] [21] no OX40 antagonists have been reported to date.
Using this Alphascreen assay, we observed that PV, a 31amino-acid peptide, was able to decrease the signal by 73% when tested at a concentration of 50 µM, and a full dose-response curve generated a K i value of 7.4 µM. This peptide appeared to be selective for the OX40L:OX40 interaction, having no effect on the binding of the Fas receptor and the CD30 receptor to their respective ligands. These results could give us a basis on which to perform a further screen of small peptides, or even small molecules, to develop potent and selective inhibitors of OX40 binding.
Our finalized assay has marked advantages over other approaches currently used to measure protein-protein interactions. The fusion protein was constructed with only a small biological linker and displayed binding characteristics similar to unmodified OX40L. The assay is rapid in terms of development time and reagent preparation and amenable to automated HTS in a 384-well format with the possibility of further miniaturization into a 1536well format. 35 The nonradioactive design makes it more attractive and inexpensive. Indeed, an alternative time-resolved energy transfer 39 approach has previously been described for another member of the TNF receptor superfamily, the herpes virus entry mediator (HVEM) receptor. In this case, the extracellular domain of the HVEM receptor was expressed as an IgG fusion protein, and a signal was generated as a result of energy transfer from a europium chelate on the HVEM receptor to an allophycocyanin acceptor on the ligand. This further highlights the success of using IgG domains as fusion proteins to measure protein-protein interactions. We believe that this assay is sensitive enough to provide a screening platform to identify peptides and small molecules that may inhibit an interaction, not only between OX40L:OX40 but also against many other protein-binding partners.
CONCLUSIONS
The migration of a significant number of assay technologies away from radioactivity and into a homogeneous format remains a common objective of HTS groups. The extent to which this trend will occur depends on, among other factors, the target class, the speed of development, and the robustness of the assay compared with more conventional radioactive or separation-based approaches. Using Alphascreen technology, we have developed a homogeneous, nonradioactive assay in a 384-well format, suitable to screen for compounds acting specifically on the OX40:OX40L interaction. The assay can be performed in 2 h with just 2 addition steps and excellent Z′ values in the presence of 1% DMSO, indicative of a performance that is superior to the minimum requirements for high-throughput applications.
